Protagonist Therapeutics, Inc.
PTGX
$155.10
$3.682.43%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 278.72% | 657.94% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 278.72% | 657.94% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 278.72% | 657.94% | |||
| SG&A Expenses | -4.74% | 16.12% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.84% | 3.85% | |||
| Operating Income | 4,452.14% | 92.76% | |||
| Income Before Tax | 7,138.67% | 105.22% | |||
| Income Tax Expenses | 250.80% | -325.53% | |||
| Earnings from Continuing Operations | 4,204.76% | 108.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4,204.76% | 108.52% | |||
| EBIT | 4,452.14% | 92.76% | |||
| EBITDA | 5,010.92% | 93.52% | |||
| EPS Basic | 4,150.95% | 108.38% | |||
| Normalized Basic EPS | 7,046.58% | 105.13% | |||
| EPS Diluted | 4,480.00% | 107.16% | |||
| Normalized Diluted EPS | 7,094.55% | 104.73% | |||
| Average Basic Shares Outstanding | 1.30% | 1.65% | |||
| Average Diluted Shares Outstanding | 0.73% | 10.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||